Skip to content

US · IRD · BIOTECHNOLOGY

Opus Genetics, Inc. (IRD) intrinsic value and stock valuation

$3.99as of 2026-11-21 · Mkt cap 312.1M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Opus Genetics, Inc. DCF and intrinsic value

InvestorsCraft values IRD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IRD’s statements →

Opus Genetics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Durham, NC 27713 opusgtx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$14.2M
20192025
Net income
-$-49.59M
20192025
Free cash flow
-$-35.25M
20192025
Total equity
$15.4M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$14.2M$11M$19.1M$39.9M$590K
Operating income-$-38.6M-$-62.07M-$-10.56M$18.2M-$-22.7M
Net income-$-49.59M-$-57.53M-$-9.99M$17.9M-$-56.69M
EPSd-$-79.7K-$-2.15M-$-462.71K$868.4K-$-3.82M
Operating cash flow-$-35.25M-$-25.58M-$-1.11M$14.3M-$-19.37M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-35.25M-$-25.58M-$-1.11M$14.3M-$-19.37M
Total assets$50.2M$36.9M$54M$49M$26.1M
Total debt$0.00$0.00$0.00$0.00$540K
Net debt-$-45.09M-$-30.32M-$-50.5M-$-42.63M-$-24M
Total equity$15.4M$6.72M$49.9M$46.2M$22.2M
Cash and short-term investments$45.1M$30.3M$50.5M$42.7M$24.8M
Income statement
20252024202320222021
Revenue$14.2M$11M$19.1M$39.9M$590K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$14.2M$11M$19.1M$39.9M$590K
Research and development expenses$30.8M$26.9M$17.7M$14.4M$15.2M
Selling, general and administrative expenses$22M$18.2M$12M$7.27M$8.12M
Other expenses$0.00$28M$0.00$0.00$0.00
Operating expenses$52.8M$73.1M$29.6M$21.6M$23.3M
Cost and expenses$52.8M$73.1M$29.6M$21.6M$23.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.47M$0.00$1.33M$10K$0.00
Depreciation and amortization$50K$10K$10K$0.00$0.00
Ebitda-$-48.07M-$-57.52M-$-9.97M$18.2M-$-56.69M
Operating income-$-38.6M-$-62.07M-$-10.56M$18.2M-$-22.7M
Total other income/expenses, net-$-10.99M$4.54M$590K-$-20K-$-33.99M
Income before tax-$-49.59M-$-57.53M-$-9.97M$18.2M-$-56.69M
Income tax expense$0.00$0.00$10K$320K$0.00
Net income-$-49.59M-$-57.53M-$-9.99M$17.9M-$-56.69M
Weighted average shares outstanding$622.2M$26.7M$21.6M$19.9M$14.9M
Weighted average diluted shares outstanding$622.2M$26.7M$21.6M$20.6M$14.9M
Balance sheet
20252024202320222021
Cash and short-term investments$45.1M$30.3M$50.5M$42.7M$24.8M
Net receivables$3.17M$5.77M$2.33M$4.85M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$50M$36.6M$54M$49M$26.1M
Property, plant and equipment, net$200K$250K$0.00$10K$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$200K$250K$0.00$10K$10K
Total assets$50.2M$36.9M$54M$49M$26.1M
Accounts payable$3.29M$3.15M$2.15M$1.07M$1.58M
Short-term debt$0.00$0.00$0.00$0.00$540K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.78M$11.3M$4.04M$2.75M$3.85M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$27.1M$18.8M$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$34.9M$30.1M$4.04M$2.75M$3.85M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-188.59M-$-139M-$-81.47M-$-71.48M-$-89.37M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$15.4M$6.72M$49.9M$46.2M$22.2M
Total investments$0.00$0.00$10K$50K$220K
Total debt$0.00$0.00$0.00$0.00$540K
Net debt-$-45.09M-$-30.32M-$-50.5M-$-42.63M-$-24M
Cash flow statement
20252024202320222021
Net income-$-49.59M-$-57.53M-$-9.99M$17.9M-$-56.69M
Depreciation and amortization$50K$10K$10K$0.00$0.00
Stock-based compensation$3.4M$3.36M$3.51M$1.81M$1.91M
Change in working capital-$-2.15M$3.09M$4.08M-$-5.55M$180K
Accounts receivable$2.61M-$-3.44M$2.52M-$-4.85M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$10K$220K$1.08M-$-520K$380K
Net cash provided by operating activities-$-35.25M-$-25.58M-$-1.11M$14.3M-$-19.37M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$1.21M$0.00$0.00-$-100K
Common stock issued$49.2M$4.5M$9.23M$4.43M$28.5M
Common stock repurchased-$-150K-$-80K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$50M$4.19M$8.98M$3.79M$27.6M
Net change in cash$14.8M-$-20.18M$7.87M$18.1M$8.13M
Cash at end of period$45.1M$30.3M$50.5M$42.6M$24.5M
Operating cash flow-$-35.25M-$-25.58M-$-1.11M$14.3M-$-19.37M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-35.25M-$-25.58M-$-1.11M$14.3M-$-19.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Opus Genetics, Inc.

        Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

        CEO
        George Magrath
        Employees
        28
        Beta
        0.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Opus Genetics, Inc. (IRD)?

        Opus Genetics, Inc. (IRD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IRD undervalued?

        IRD trades at a price of $3.99 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.